Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol

Shearwood McClelland, Tim Lautenschlaeger, Yong Zang, Nasser H. Hanna, Kevin Shiue, Aaron P. Kamer, Namita Agrawal, Susannah G. Ellsworth, Ryan M. Rhome, Gordon A. Watson

Research output: Contribution to journalReview article

Abstract

Introduction: Up to 20% of patients with brain metastases treated with immune checkpoint inhibitor (ICI) therapy and concomitant stereotactic radiosurgery (SRS) suffer from symptomatic radiation necrosis. The goal of this study is to evaluate Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI) on six-month symptomatic radiation necrosis rates. Methods: This study is a prospective single arm Phase I pilot study which will recruit patients with brain metastases receiving ICI delivered within 30 days before SRS. All patients will be treated with RADREMI dosing, which involves SRS doses of 18 Gy for 0−2 cm lesions, 14 Gy for 2.1−3 cm lesions, and 12 Gy for 3.1−4 cm lesions. All patients will be monitored for six-month symptomatic radiation necrosis (defined as a six-month rate of clinical symptomatology requiring steroid administration and/or operative intervention concomitant with imaging findings consistent with radiation necrosis) and six-month local control. We expect that RADREMI dosing will significantly reduce the symptomatic radiation necrosis rate of concomitant SRS + ICI without significantly sacrificing the local control obtained by the present RTOG 90−05 SRS dosing schema. Local control will be defined according to the Response Assessment in Neuro-Oncology (RANO) criteria. Discussion: This study is the first prospective trial to investigate the safety of dose-reduced SRS in treatment of brain metastases with concomitant ICI. The findings should provide fertile soil for future multi-institutional collaborative efficacy trials of RADREMI dosing for this patient population. Trial Registration: Clinicaltrials.gov identifier: NCT04047602 (registration date: July 25, 2019).

Original languageEnglish (US)
Pages (from-to)500-506
Number of pages7
JournalReports of Practical Oncology and Radiotherapy
Volume25
Issue number4
DOIs
StatePublished - Jul 1 2020

Keywords

  • Brain metastases
  • Gamma knife
  • Immunotherapy
  • Linear accelerator
  • Stereotactic radiosurgery
  • Symptomatic radiation necrosis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol'. Together they form a unique fingerprint.

  • Cite this

    McClelland, S., Lautenschlaeger, T., Zang, Y., Hanna, N. H., Shiue, K., Kamer, A. P., Agrawal, N., Ellsworth, S. G., Rhome, R. M., & Watson, G. A. (2020). Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol. Reports of Practical Oncology and Radiotherapy, 25(4), 500-506. https://doi.org/10.1016/j.rpor.2020.04.007